Skip to main content

MIPrecise - Robust biomarker binders, probes and assays for sustainable precision medicine

0

Development and use of stable synthetic antibodies and designed receptors as diagnostic tools to reduce cancer treatment disparities

The Department of Drug Sciences of the University of Pavia participates to a four-year project (MIPrecise) funded by the EC HORIZON–MSCA-2024-DN Grant Agreement No. 101226400, coordinated by Malmö University. The project starts 1st November 2025 and will end in October 2029.

The UNIPV Unit is coordinated by Prof. Ersilia De Lorenzi.

MIPrecise is a Doctoral Network that will train 13 Doctoral Candidates in developing synthetic antibodies (SAs) for guiding personalised therapies, for home based sampling and for biomarker discovery.

The project addresses inequalities in cancer health care by enabling at-home sampling and/or enrichment of scarce biomarkers and whole cells based on novel SAs and probes.

MIPrecise will thereby aim to make progress related to the following cancer relevant topics:

  • Assays for guiding personalized therapies based on kinase inhibitors
  • Robust assays and home based sampling for small cell lung cancer
  • Discovery of new biomarkers for more precise cancer diagnostics
  • Fast and sensitive liquid biopsies for assessment of tumour aggressiveness

The network is made up of twelve academic and industrial partners from six European countries (Sweden, Italy, United Kingdom, Germany, Norway, Denmark) providing international, intersectoral and interdisciplinary training that brings together chemists, material scientists, biologists and clinicians, to give each of our doctoral candidates a rich joint-doctoral training experience in the fields of molecular imprinting, smart materials, proteomics, single cell analysis, nanomedicine and clinical diagnostics.

Vacancies for 13 Doctoral Candidates positions will be open from Nov 1st 2025. UNIPV will enrol 1 Doctoral Candidate within the PhD School in Chemical and Pharmaceutical Sciences and Industrial Innovation.

Overall, MIPrecise is seeking for 13 outstanding, highly motivated Doctoral Candidates who meet the global MSCA criteria.